Immuneering Corp’s recently made public that its Director Schall Thomas J. acquired Company’s shares for reported $0.1 million on Jan 15 ’26. In the deal valued at $4.67 per share,21,645 shares were bought. As a result of this transaction, Schall Thomas J. now holds 74,530 shares worth roughly $0.36 million.
Then, Hall Brett Matthew bought 2,298 shares, generating $10,502 in total proceeds. Upon buying the shares at $4.57, the CHIEF SCIENTIFIC OFFICER now owns 376,496 shares.
Before that, Neufeld Leah R bought 2,626 shares. Immuneering Corp shares valued at $10,906 were divested by the CHIEF PEOPLE OFFICER at a price of $4.15 per share. As a result of the transaction, Neufeld Leah R now holds 25,970 shares, worth roughly $0.12 million.
Leerink Partners initiated its Immuneering Corp [IMRX] rating to an Outperform in a research note published on October 31, 2025; the price target was $15. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who decreased its forecast for the stock in mid December from “an Equal-weight” to “an Underweight”. Needham also remained covering IMRX and reiterated its “Buy” recommendation on March 15, 2024. TD Cowen revised its rating on March 15, 2024. It rated IMRX as “a Market perform” which previously was an “an Outperform”.
Price Performance Review of IMRX
On Tuesday, Immuneering Corp [NASDAQ:IMRX] saw its stock jump 4.37% to $4.78. Over the last five days, the stock has gained 13.27%. Immuneering Corp shares have risen nearly 143.88% since the year began. Nevertheless, the stocks have fallen -27.36% over the past one year.
How much short interest is there in Immuneering Corp?
A steep rise in short interest was recorded in Immuneering Corp stocks on 2025-12-31, growing by 3.64 million shares to a total of 10.92 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 7.29 million shares. There was a rise of 33.28%, which implies that there is a positive sentiment for the stock.
